All stock lists
Unlock the score
Palisade Bio, Inc. (NASDAQ:PALI)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.23-0.10 (-7.52%)
Market cap
$214M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 30, 2007
Website
Insider Score
/ 100
PALI Insider Score
PALISADE BIO, INC. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
Financial Health Score
Fair
From PALI’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $500K
- Net income
- -$31.9M
- Net margin
- -6388.2%
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $125.2M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $127.3M
- Current liabilities
- $5.2M
- Current ratio
- 24.26
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$18.2M
- Free cash flow
- -$18.2M
- FCF margin
- -3638.0%
Dilution & runway0 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 211.4M
- Share growth (1y)
- 4306.4%
- Cash runway
- 83 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
PALI Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 500.00 K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 500.00 K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 4.80 M | 4.35 M | 3.81 M | 1.53 M | 1.17 M | 1.36 M |
| R&D Expense | 7.40 M | 6.40 M | 6.17 M | 1.39 M | 1.68 M | 950.00 K |
| Operating Expenses | 12.20 M | 10.75 M | 9.98 M | 2.92 M | 2.84 M | 2.31 M |
| Operating Income | -11.70 M | -10.75 M | -9.98 M | -2.92 M | -2.84 M | -2.31 M |
| Pretax Income | -10.57 M | -9.60 M | -8.90 M | -2.87 M | -2.78 M | -2.23 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -10.57 M | -9.60 M | -8.90 M | -2.87 M | -2.78 M | -2.23 M |
| EPS (Basic) | -0.05 | -0.05 | -0.06 | -0.38 | -0.58 | -0.46 |
| EPS (Diluted) | -0.05 | -0.05 | -0.06 | -0.38 | -0.58 | -0.46 |
| Shares Outstanding | 211.38 M | 209.66 M | 55.67 M | 7.47 M | 4.80 M | 4.80 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.